Dr Arron Tolley on Aptamer Group’s new optimer developments – ICYMI [Video]

Aptamer Group PLC (AIM:APTA) CEO Dr Arron Tolley talked with Proactive about recent announcements that highlight significant progress in their targeted drug delivery solutions.

Tolley explained that Aptamer Group’s focus on precision medicine aims to tackle the challenges of systemic drug administration, offering targeted solutions to improve patient care and reduce side effects.

Proactive: Aaron, very good to speak with you. Could you start by telling us why yesterday’s announcement is big news for Aptamer Group?

Arron Tolley: Thank you. Yeah. It’s a big announcement really because targeted drug delivery is a huge problem. It’s a huge and growing market. Lots of big pharmaceutical companies are evaluating ways to specifically deliver drugs to diseased tissues, and doing that is critical to improve patient care and reduce side effects.

The problem with most medicines is that they’re required to be systemically administered, which basically means injecting them or having the molecules travel all over the body.

But for …